A

    Arcutis Biotherapeutics Inc (ARQT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $23.97
    +0.19 (+0.80%)

    Market Cap: $2.99B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    79%(22/28)
    Avg Surprise
    +16.48%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$0.16
    Range$0.09 - $0.20
    6 analysts
    EPS Revisions
    3
    0
    7d
    3
    0
    30d
    EPS Estimate Drift
    90d ago$0.08-52.0%
    60d ago$0.08-52.0%
    30d ago$0.08-52.0%
    7d ago$0.08-50.5%
    Current$0.16
    Revenue Consensus
    $142M
    Range$140M - $146M
    6 analysts
    Dec 31, 2026
    EPS Consensus$0.26
    Range$0.05 - $0.47
    6 analysts
    Revenue Consensus
    $172M
    Range$165M - $184M
    8 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.26---
    Sep 26EST
    		-$0.16---
    Jun 26
    		$0.11$0.09+22.22%Beat+184.6%
    Mar 26
    		$-0.09$-0.06-50.00%Miss+55.0%
    Dec 25
    		$0.13$0.09+46.73%Beat+244.4%
    Sep 25
    		$0.06$-0.09+166.67%Beat+118.2%
    Jun 25
    		$-0.13$-0.16+18.75%Beat+69.0%
    Mar 25
    		$-0.20$-0.21+4.76%Beat+37.5%
    Dec 24
    		$-0.09N/A+65.95%Beat+87.5%
    Sep 24
    		$-0.33$-0.42+21.43%Beat+54.8%
    Jun 24
    		$-0.42$-0.53+20.75%Beat+63.8%
    Mar 24
    		$-0.32N/A+56.16%Beat+75.6%
    Dec 23
    		$-0.72$-0.80+10.00%Beat+39.0%
    Sep 23
    		$-0.73$-0.91+19.78%Beat+61.4%
    Jun 23
    		$-1.16$-1.25+7.20%Beat+11.5%
    Mar 23
    		$-1.31$-1.26-3.97%Miss-3.1%
    Dec 22
    		$-1.18$-1.42+16.90%Beat+16.9%
    Sep 22
    		$-1.89$-1.75-8.00%Miss-65.8%
    Jun 22
    		$-1.31$-1.42+7.75%Beat-56.0%
    Mar 22
    		$-1.27$-1.52+16.45%Beat-67.1%
    Dec 21
    		$-1.42$-1.49+4.70%Beat-79.7%
    Sep 21
    		$-1.14$-1.19+4.20%Beat-12.9%
    Jun 21
    		$-0.84$-0.93+9.68%Beat+10.6%
    Mar 21
    		$-0.76$-0.97+21.65%Beat+33.9%
    Dec 20
    		$-0.79$-0.86+8.14%Beat+87.2%
    Sep 20
    		$-1.01$-0.90-12.22%Miss+86.7%
    Jun 20
    		$-0.94$-0.84-11.90%Miss-452.9%
    Mar 20
    		$-1.15$-0.85-35.29%Miss-
    Dec 19
    		$-6.18$-9.21+32.90%Beat-
    Sep 19
    		$-7.60$-7.60+0.00%Beat-
    Jun 19
    		$-0.17$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio114.14EV/EBITDA66.07x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin6.15%Operating Margin12.70%
    ROE15.90%ROIC8.77%
    Financial Health
    Debt/Equity0.49xInterest Coverage2.14x
    Current Ratio2.92xQuick Ratio2.67x
    Trading Statistics
    Beta1.53Avg Volume1.83M
    52-Week High$31.7752-Week Low$15.13

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$25.08
    SMA 20$25.59
    SMA 50$26.61
    SMA 200$25.62
    EMA 10$24.88
    EMA 20$25.46
    EMA 50$25.72
    EMA 200$24.14

    MACD

    Line: -0.62Signal: -0.42Hist: -0.20

    ADX

    ADX: 17.4+DI: 16.4-DI: 30.0

    Aroon & PSAR

    Aroon Up32.0
    Aroon Down100.0
    PSAR$26.23

    Bollinger Bands

    Upper Band$27.33
    Lower Band$23.84
    %B Position1364%(Upper)
    Band Width0.04

    RSI (14-Day)

    Neutral
    36.8

    Momentum Oscillators

    Stoch %K11.9
    Stoch %D14.0
    Williams %R-80.9
    ROC (10d)-6.4%
    Momentum-1.64
    CCI (20d)-178.9
    MFI (14d)26.3

    Volatility Measures

    ATR (14d)$1.05(4.4%)
    StdDev (20d)0.87
    Hist Vol38.6%(Moderate)

    Volume Flow

    VWAP$23.75
    OBV36.3M
    AD Line25.0M
    CMF (20d)-0.120

    Volume Metrics

    Avg Vol (20d)1.8M
    Vol Ratio0.8x
    VWMA (20d)$25.62

    Pivot Points

    R3$25.67
    R2$25.27
    R1$24.53
    Pivot Point$24.13
    S1$23.39
    S2$22.99
    S3$22.25

    Advanced Oscillators

    TSI-16.78
    Ultimate Osc43.3
    KST-70.28

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$129.86M$105.40M$129.50M$99.22M$81.50M$65.85M$71.36M$44.76M$30.86M$49.57M$13.53M$38.11M
    Cost of Revenue$10.94M$9.78M$11.69M$8.69M$7.49M$8.83M$6.91M$5.50M$3.46M$3.26M$2.25M$1.18M
    Gross Profit$118.92M$95.61M$117.81M$90.53M$74.01M$57.02M$64.45M$39.25M$27.39M$46.31M$11.28M$36.93M
    Operating Expenses$102.49M$104.70M$99.43M$82.01M$88.62M$81.55M$72.09M$78.32M$77.47M$77.94M$72.45M$73.83M
    R&D$20.36M$30.63M$20.45M$19.60M$19.45M$17.54M$14.48M$19.50M$19.30M$23.14M$23.77M$26.24M
    SG&A$82.14M$74.08M$78.98M$62.40M$69.17M$64.00M$57.61M$58.82M$58.17M$54.79M$48.67M$47.59M
    Operating Income$16.43M$-9,089,000$18.39M$8.53M$-14,611,000$-24,529,000$-7,632,000$-39,066,000$-50,077,000$-31,622,000$-61,169,000$-36,904,000
    Interest Income$2.28M$2.27M$0$0$2.08M$2.54M$0$0$0$0$0$0
    Interest Expense$3.41M$4.37M$3.00M$3.07M$3.03M$2.98M$5.55M$6.65M$7.48M$7.48M$7.76M$7.56M
    Income Before Tax$15.14M$-11,202,000$17.86M$7.49M$-15,544,000$-24,781,000$-10,465,000$-41,537,000$-52,332,000$-35,058,000$-66,194,000$-41,742,000
    Income Tax Expense$136,000$93,000$470,000$80,000$342,000$279,000$323,000$0$0$324,000$90,000$3.02M
    Net Income$15.01M$-11,295,000$17.39M$7.41M$-15,886,000$-25,060,000$-10,788,000$-41,537,000$-52,332,000$-35,382,000$-66,284,000$-44,765,000
    EBITDA$16.61M$-8,729,000$12.54M$10.57M$-14,723,000$-22,216,000$-21,823,000$-35,305,000$-47,049,000$-28,945,000$-72,234,000$-35,328,000
    EBIT$16.27M$-9,109,000$11.97M$10.56M$-14,591,000$-24,336,000$-21,040,000$-34,884,000$-44,848,000$-27,578,000$-70,949,000$-34,183,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ARQT

    News

    Insider Decision Unfolding At Arcutis Biotherapeutics: Terrie Curran Exercises Options, Resulting In $18K

    Arcutis Biotherapeutics Board Member Terrie Curran exercised stock options for 1,072 shares of ARQT, valued at $18,642, as revealed in an SEC filing on August 24. The company's stock was up by 0.81% at $24.9 following the transaction. The article also provides an analysis of Arcutis Biotherapeutics' financial performance, highlighting strong revenue growth and gross margin but noting challenges in EPS and debt management.

    Benzinga•8/25/26•
    Somewhat-Bullish

    Arcutis Biotherapeutics Director Terrie Curran Executes Stock Option and Sells Shares on August 20, 2026

    Arcutis Biotherapeutics Director Terrie Curran executed stock options for 1,072 shares at $7.51 per share and simultaneously sold all these shares at a weighted average price of $26.0376 on August 20, 2026. Following these transactions, Curran's direct beneficial ownership in Arcutis Biotherapeutics (NASDAQ:ARQT) is 23,526 shares, and she retains 11,148 stock options expiring in 2033. The transactions were detailed in a Form 4 filed with the SEC on August 24, 2026.

    Kalkine Media•8/24/26•
    Neutral

    Tejara Capital Ltd Buys Shares of 113,084 Arcutis Biotherapeutics, Inc. $ARQT

    Tejara Capital Ltd has acquired a new position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), purchasing 113,084 shares valued at approximately $2.965 million, making it their 24th biggest holding. Several other hedge funds also adjusted their stakes in ARQT, while company insiders sold shares totaling over $288,000. Analyst ratings indicate a "Moderate Buy" consensus with an average price target of $35.57.

    MarketBeat•8/21/26•
    Somewhat-Bullish

    Arcutis (NASDAQ: ARQT) director to sell 1,072 shares

    A director at Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), Terrie Curran, has filed a Rule 144 notice to sell 1,072 shares of the company's common stock. These shares, valued at $27,912.35, were acquired through a stock option exercise on May 31, 2023, and are planned to be sold via Merrill Lynch on the NASDAQ. This filing indicates an insider transaction and is considered to have a neutral impact and sentiment.

    Stock Titan•8/20/26•
    Somewhat-Bearish

    Arcutis Biotherapeutics (NASDAQ:ARQT) Director Howard Welgus Sells 4,730 Shares

    Arcutis Biotherapeutics Director Howard Welgus sold 4,730 shares of the company's stock for $123,831.40, reducing his ownership by 11.48%. This transaction occurred under a Rule 10b5-1 trading plan. The company recently reported strong quarterly earnings of $0.11 per share and revenue of $129.86 million, both exceeding analyst expectations.

    MarketBeat•8/19/26•
    Somewhat-Bullish

    Frequently Asked Questions About ARQT

    Does ARQT pay dividends?
    Arcutis Biotherapeutics Inc (ARQT) does not currently pay a regular dividend.
    What is ARQT's P/E ratio?
    Arcutis Biotherapeutics Inc has a price-to-earnings (P/E) ratio of 114.14.
    What is ARQT's market cap?
    Arcutis Biotherapeutics Inc (ARQT) has a market capitalization of $2.99B with a current stock price of $23.97.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In